Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.
- CAS Registry Number
- 62732-44-9
- Molecular formula
- C12H16N2
- Molecular weight
- 188.27 g/mol
- Drug class
- Reversible acetylcholinesterase inhibitorpotassium-channel blocker and cholinergic neuromodulator
- Mechanism of action
- Reversibly inhibits acetylcholinesterase, increasing acetylcholine at central and peripheral cholinergic synapses. It also blocks voltage-gated potassium channels, prolonging neuronal action potentials and enhancing presynaptic calcium entry and neurotransmitter release.
- Indications / reported uses
- Symptomatic treatment of acquired mononeuropathies and polyneuropathies in adults.
- Adjunctive symptomatic treatment of myasthenia gravis and selected bulbar dysfunction during recovery after brainstem ischaemic stroke.
- Symptomatic treatment of mild-to-moderately severe Alzheimer’s disease and intestinal atony, where authorised under the revised European product information. Other previously listed uses were restricted or removed following the EMA review in September 2026.
Sources: https://www.ema.europa.eu/en/medicines/human/referrals/ipidacrine-containing-medicinal-products · https://www.ema.europa.eu/en/documents/referral/ipidacrine-containing-medicinal-products-article-31-referral-ema-concludes-review-ipidacrine-containing-medicines_en.pdf